(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/123574 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2019/065581

(22) International Filing Date:
11 December 2019 (11.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/779,028 13 December 2018 (13.12.2018) US

(71) Applicant: **SAREPTA THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventors: **SCHNELL, Frederick, Joseph**; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). **CAI, Baozhong**; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). **DESAI, Ankur**; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). **BESTWICK, Richard, K.**; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).


(74) Agent: **VERNI, Christopher** et al.; Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY



(I)

(57) Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 50 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein T, Nu, n, and R^{100} are defined herein.

WO 2020/123574 A1